Leerink lowered the firm’s price target on Tandem Diabetes (TNDM) to $38 from $48 and keeps an Outperform rating on the shares ahead of quarterly results. The firm is updating estimates to reflect financial statement disclosures and its updated views, and price targets of several names in the space to reflect recent changes in valuation premiums.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes downgraded to Sell from Neutral at Citi
- Wells says CBP proposal for CGMs expected, insulin pumps inclusion ‘a surprise’
- Diabetes device maker shares slide after payment scheduling proposal
- Diabetes stocks rally after RFK comments on HHS campaign
- Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls